Emiltatug ledadotin
Emiltatug ledadotin (Emi-Le; XMT-1660) is an antibody-drug conjugate (ADC) targeting B7-H4 (VTCN1). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), and is site-specifically conjugated via GlycoConnect click chemistry, with a total of 6 DolaLock Auristatin F-HPA (AF-HPA) anti-tubulin payloads conjugated per antibody (DAR-6). Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2855974-40-0
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
|
tubulin |
B7-H4 (VTCN1) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
In Vivo
Emiltatug ledadotin (2.3/0.075-4.7/0.15 mg/kg; i.v.; single dose) induces complete, sustained tumor regression in the MX-1 breast cancer CDX model following a single intravenous dose across multiple dose levels[2].
Emiltatug ledadotin (2.3/0.075-4.6/0.15 mg/kg; i.v.; single dose) induces complete, sustained tumor regression in the OV2423 ovarian cancer PDX model following a single intravenous dose across multiple dose levels[2].
Emiltatug ledadotin (4.6/0.15 mg/kg; i.v.; single dose) induces potent tumor growth inhibition in the CTG-1692 ovarian cancer PDX model following a single intravenous dose of 4.6/0.15 mg/kg (antibody/payload)[2].
Emiltatug ledadotin (1.5/0.05-4.6/0.15 mg/kg; i.v.; single dose) induces complete, sustained tumor regression in the PD-1 refractory mBR9013 syngeneic breast cancer model following a single intravenous dose across multiple dose levels[2].
Emiltatug ledadotin (4.7/0.15 mg/kg; i.v.; single dose) exhibits antitumor activity in 43% of a diverse panel of breast cancer PDX models following a single intravenous dose of 4.7/0.15 mg/kg (antibody/payload), with activity correlating with B7-H4 expression[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HSD: Athymic Nude-Foxn1mu (female)[2]
-
Dosage:1.5/0.05 mg/kg; 2.3/0.075 mg/kg; 4.7/0.15 mg/kg (antibody/payload)
-
Administration:i.v.; single dose
-
Result:Induced complete tumor regression at all tested doses.
Resulted in sustained tumor regression with mean tumor volume remaining near 0 mm3 through day 63 post-treatment at the 4.7/0.15 mg/kg dose.
-
Animal Model:Crl:NU(Ncr)-Foxn1mu (female)[2]
-
Dosage:2.3/0.075 mg/kg; 4.7/0.15 mg/kg (antibody/payload)
-
Administration:i.v.; single dose
-
Result:Induced complete tumor regression at both tested doses.
Resulted in sustained tumor regression with mean tumor volume remaining near 0 mm3 through day 63 post-treatment at the 4.7/0.15 mg/kg dose.
-
Animal Model:BALB/cNj-Foxn1nu/Gpt (female)[2]
-
Dosage:2.3/0.075 mg/kg; 4.6/0.15 mg/kg (antibody/payload)
-
Administration:i.v.; single dose
-
Result:Induced complete tumor regression at both tested doses.
Resulted in sustained tumor regression with mean tumor volume remaining near 0 mm3 through day 70 post-treatment at the 4.6/0.15 mg/kg dose.
-
Animal Model:HSD: Athymic Nude-Foxn1mu (female)[2]
-
Dosage:4.6/0.15 mg/kg (antibody/payload)
-
Administration:i.v.; single dose
-
Result:Induced significant tumor growth inhibition, with mean tumor volume remaining near baseline through day 56 post-treatment, while vehicle-treated tumors grew to over 2000 mm3.
-
Animal Model:FVB/NJ (female; PD-1 refractory model)[2]
-
Dosage:1.5/0.05 mg/kg; 4.6/0.15 mg/kg (antibody/payload)
-
Administration:i.v.; single dose
-
Result:Induced complete tumor regression at both tested doses.
Resulted in sustained tumor regression with mean tumor volume remaining near 0 mm3 through day 49 post-treatment at the 4.6/0.15 mg/kg dose.
Showed no antitumor activity with anti-PD-1 treatment.
-
Animal Model:HSD: Athymic Nude-Foxn1mu (female)[2]
-
Dosage:4.7/0.15 mg/kg (antibody/payload)
-
Administration:i.v.; single dose
-
Result:Achieved median best response (MBR) ≤ -0.3 (≥ 30% tumor shrinkage) in 12/28 (43%) models.
Saw tumor volume reduction in 13/28 (46%) models.
Had more frequent responses in TNBC models (9/15, 60%) than ER-positive models (3/13, 23%).
Showed activity correlating with B7-H4 expression, with 9/13 (69%) models with high tumor proportion score (TPS ≥ 75) achieving MBR ≤ -0.3.
Product Details
Chemical Information
-
CAS No. 2855974-40-0
-
SMILES
[Emiltatug ledadotin]
-
Synonyms
Emi-Le; XMT-1660
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Emiltatug ledadotin Related Classifications
HY-177542 Related Classifications
Powered by Bioz
Keywords
- Emiltatug ledadotin
- 2855974-40-0
- Emi-Le
- XMT-1660
- XMT1660
- XMT 1660
- XMT-1660
- Antibody-Drug Conjugates (ADCs)
- Microtubule/Tubulin
- CD276/B7-H3
- Antibody-Drug Conjugates
- ADC
- B7 homolog 3 protein
- auristatin F-HPA
- microtubules
- HEK293-B7-H4 cells
- syngeneic breast cancer models
- B7-H4
- breast cancer
- triple-negative breast cancer
- ovarian cancer
- ovarian cancer xenograft models
- xenograft breast cancer models
- Inhibitor
- inhibitor
- inhibit